Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Abstract Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe
acute respiratory syndrome 2 (SARS-CoV-2). Throughout the pandemic, evidence on the …

Background Remdesivir is an antiviral drug approved for the treatment of COVID‐19, whose
developmental toxicity remains unclear. More information about the safety of remdesivir is …

Abstract Purpose The SARS-CoV-2 pandemic has rapidly spread worldwide and, among the
others, the male gender was quickly recognized as an independent risk factor for both the …

Remdesivir (RDV) is the mainstay antiviral therapy for moderate to severe COVID-19.
Although remdesivir was the first drug approved for COVID-19, information about its efficacy …

The COVID-19 pandemic posed a significant challenge for clinicians in managing pregnant
women, who were at high risk of virus transmission and severe illness. While the WHO …

Background Pregnant people with COVID-19 experience higher risk for severe disease and
adverse pregnancy outcomes, but no pharmacokinetic (PK) data exist to support dosing of …

In January 2022, as the Omicron variant of severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) surged globally [1], multiple outpatient therapies showed a reduction in …

Remdesivir has appeared to be the most effective medication against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to …

Women who are pregnant and who have COVID-19 infection have unique challenges from
both a medical and non-medical perspective. In a post-pandemic society, there are new …